You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


NICE recommendation expands patient eligibility for AbbVie’s Ozurdex

Treatment becomes an option for treating visual impairment caused by diabetic macular oedema, regardless of lens status.